{"id": "article-30267_0", "title": "Topiramate -- Continuing Education Activity", "content": "Topiramate is a medication used to manage and treat epilepsy and migraine, and it is in the second-generation anti-epileptic drugs class of drugs. In addition, Topiramate has approval for chronic weight management for individuals with a body mass index over 30. Topiramate received FDA approval in 1996 for treating epilepsy as monotherapy or adjunctive therapy. This activity will highlight the indications, mechanism of action, and adverse event profile pertinent to interprofessional team members in managing patients with epilepsy, migraine, and related conditions. It also lists other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions, toxicity, and monitoring related to topiramate therapy.", "contents": "Topiramate -- Continuing Education Activity. Topiramate is a medication used to manage and treat epilepsy and migraine, and it is in the second-generation anti-epileptic drugs class of drugs. In addition, Topiramate has approval for chronic weight management for individuals with a body mass index over 30. Topiramate received FDA approval in 1996 for treating epilepsy as monotherapy or adjunctive therapy. This activity will highlight the indications, mechanism of action, and adverse event profile pertinent to interprofessional team members in managing patients with epilepsy, migraine, and related conditions. It also lists other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions, toxicity, and monitoring related to topiramate therapy."}
{"id": "article-30267_1", "title": "Topiramate -- Continuing Education Activity", "content": "Objectives: Describe the mechanism of action of topiramate. Identify the indications of topiramate. Review the appropriate monitoring of topiramate. Outline some interprofessional team strategies for improving care coordination and communication to advance topiramate and improve outcomes. Access free multiple choice questions on this topic.", "contents": "Topiramate -- Continuing Education Activity. Objectives: Describe the mechanism of action of topiramate. Identify the indications of topiramate. Review the appropriate monitoring of topiramate. Outline some interprofessional team strategies for improving care coordination and communication to advance topiramate and improve outcomes. Access free multiple choice questions on this topic."}
{"id": "article-30267_2", "title": "Topiramate -- Indications", "content": "Topiramate is a\u00a0compound that belongs to the family of medications called antiepileptic drugs (AEDs). AEDs are generally used for neurologic and psychiatric purposes. [1] The primary indication for this family of drugs is\u00a0treating seizure disorders, hence the name \"antiepileptic drugs.\" These are classically used as mood stabilizers in psychiatry, although their\u00a0administrations have seen a broader application. Specifically, topiramate is an anticonvulsant drug that was initially FDA-approved in 1996 for the treatment of monotherapy in epilepsy, adjunctive therapy in epilepsy, and migraine disorder. [2]", "contents": "Topiramate -- Indications. Topiramate is a\u00a0compound that belongs to the family of medications called antiepileptic drugs (AEDs). AEDs are generally used for neurologic and psychiatric purposes. [1] The primary indication for this family of drugs is\u00a0treating seizure disorders, hence the name \"antiepileptic drugs.\" These are classically used as mood stabilizers in psychiatry, although their\u00a0administrations have seen a broader application. Specifically, topiramate is an anticonvulsant drug that was initially FDA-approved in 1996 for the treatment of monotherapy in epilepsy, adjunctive therapy in epilepsy, and migraine disorder. [2]"}
{"id": "article-30267_3", "title": "Topiramate -- Indications", "content": "Topiramate has received approval for monotherapy in epilepsy in those two years or older with primary generalized onset tonic-clonic or partial-onset seizures. [3] Adjunctive therapy is approved for adults and pediatric populations ages 2 to 16 years with primary generalized onset tonic-clonic seizures, partial-onset seizures, and those two years or older with Lennox-Gastaut syndrome-associated seizures. [4] [5] For migraine disorders,\u00a0topiramate has been approved for prophylaxis in adults (FDA, 2012). Topiramate has received approval for chronic weight management for individuals with a body mass index over 30 kg/m. [6] A fixed-dose combination of\u00a0topiramate and phentermine\u00a0is approved by FDA for the management of obesity. [7]", "contents": "Topiramate -- Indications. Topiramate has received approval for monotherapy in epilepsy in those two years or older with primary generalized onset tonic-clonic or partial-onset seizures. [3] Adjunctive therapy is approved for adults and pediatric populations ages 2 to 16 years with primary generalized onset tonic-clonic seizures, partial-onset seizures, and those two years or older with Lennox-Gastaut syndrome-associated seizures. [4] [5] For migraine disorders,\u00a0topiramate has been approved for prophylaxis in adults (FDA, 2012). Topiramate has received approval for chronic weight management for individuals with a body mass index over 30 kg/m. [6] A fixed-dose combination of\u00a0topiramate and phentermine\u00a0is approved by FDA for the management of obesity. [7]"}
{"id": "article-30267_4", "title": "Topiramate -- Indications", "content": "There are many off-label uses for\u00a0topiramate, including neuropathic pain, psychotropic drug-induced weight gain, alcohol use disorders with tobacco dependence, cluster headache prevention, binge eating disorder, bulimia nervosa, obesity with hypertension, prevention of neuralgiform attacks, adjunctive therapy in bipolar disorder, unipolar depression, borderline personality disorder, obsessive-compulsive disorder, posttraumatic stress disorder, Tourette syndrome, Prader-Willie syndrome, essential tremor. [8] [9]", "contents": "Topiramate -- Indications. There are many off-label uses for\u00a0topiramate, including neuropathic pain, psychotropic drug-induced weight gain, alcohol use disorders with tobacco dependence, cluster headache prevention, binge eating disorder, bulimia nervosa, obesity with hypertension, prevention of neuralgiform attacks, adjunctive therapy in bipolar disorder, unipolar depression, borderline personality disorder, obsessive-compulsive disorder, posttraumatic stress disorder, Tourette syndrome, Prader-Willie syndrome, essential tremor. [8] [9]"}
{"id": "article-30267_5", "title": "Topiramate -- Mechanism of Action", "content": "Although the precise mechanism of action of topiramate is unknown, there is sufficient evidence to explain the drug's anticonvulsant activity. [10] [11] Topiramate\u00a0blocks voltage-gated sodium channels, most likely leading to sustained depolarization control during seizures. [12] Topiramate\u00a0reduces membrane depolarization by AMPA/Kainate receptors. Topiramate\u00a0enhances GABA (A) receptor activity, which enhances inhibitory effects. [6] Topiramate\u00a0is a weak inhibitor of carbonic anhydrase; acidosis in the brain partially protects against seizures by downregulating NMDA receptor activity. Overall, the effect of topiramate on these channels is the leading explanation of the antiepileptic action of the drug. [13] [14] The\u00a0efficacy of topiramate in migraine is likely due to\u00a0inhibitory effects on the AMPA and kainate subtypes of glutamate receptors and, to a lesser extent, voltage-gated calcium channels. [15]", "contents": "Topiramate -- Mechanism of Action. Although the precise mechanism of action of topiramate is unknown, there is sufficient evidence to explain the drug's anticonvulsant activity. [10] [11] Topiramate\u00a0blocks voltage-gated sodium channels, most likely leading to sustained depolarization control during seizures. [12] Topiramate\u00a0reduces membrane depolarization by AMPA/Kainate receptors. Topiramate\u00a0enhances GABA (A) receptor activity, which enhances inhibitory effects. [6] Topiramate\u00a0is a weak inhibitor of carbonic anhydrase; acidosis in the brain partially protects against seizures by downregulating NMDA receptor activity. Overall, the effect of topiramate on these channels is the leading explanation of the antiepileptic action of the drug. [13] [14] The\u00a0efficacy of topiramate in migraine is likely due to\u00a0inhibitory effects on the AMPA and kainate subtypes of glutamate receptors and, to a lesser extent, voltage-gated calcium channels. [15]"}
{"id": "article-30267_6", "title": "Topiramate -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Topiramate is well absorbed from the GIT, with peak plasma levels usually achieved in 2\u00a0to 3 hours. The bioavailability is greater than 80%. Concomitant ingestion of food slows the time required to reach peak plasma concentration, but the extent of absorption is not significantly altered. Consequently, topiramate can be administered regardless of meal time. Topiramate follows linear and predictable pharmacokinetics over the recommended dose range (15\u00a0to 400 mg/day). [16] Distribution: Topiramate\u00a0has plasma proteins-plasma protein binding of (15% to 41%).\u00a0The fraction of bound topiramate decreases as blood concentration increases. Metabolism: Topiramate is metabolized by hydroxylation, hydrolysis, and glucuronidation.", "contents": "Topiramate -- Mechanism of Action -- Pharmacokinetics. Absorption: Topiramate is well absorbed from the GIT, with peak plasma levels usually achieved in 2\u00a0to 3 hours. The bioavailability is greater than 80%. Concomitant ingestion of food slows the time required to reach peak plasma concentration, but the extent of absorption is not significantly altered. Consequently, topiramate can be administered regardless of meal time. Topiramate follows linear and predictable pharmacokinetics over the recommended dose range (15\u00a0to 400 mg/day). [16] Distribution: Topiramate\u00a0has plasma proteins-plasma protein binding of (15% to 41%).\u00a0The fraction of bound topiramate decreases as blood concentration increases. Metabolism: Topiramate is metabolized by hydroxylation, hydrolysis, and glucuronidation."}
{"id": "article-30267_7", "title": "Topiramate -- Mechanism of Action -- Pharmacokinetics", "content": "Excretion: Topiramate is eliminated by renal excretion in unchanged form and as metabolites. The clearance of topiramate in adults is\u00a020 to 30 mL/min. The mean plasma elimination half-life is approximately 21 hours. The\u00a0elimination\u00a0half-life varies according to age and concomitant use of enzyme-inducing or inhibitor drugs. The clearance increases in patients taking concomitant enzyme-inducing drugs such as phenytoin, barbiturates, and carbamazepine. [16]", "contents": "Topiramate -- Mechanism of Action -- Pharmacokinetics. Excretion: Topiramate is eliminated by renal excretion in unchanged form and as metabolites. The clearance of topiramate in adults is\u00a020 to 30 mL/min. The mean plasma elimination half-life is approximately 21 hours. The\u00a0elimination\u00a0half-life varies according to age and concomitant use of enzyme-inducing or inhibitor drugs. The clearance increases in patients taking concomitant enzyme-inducing drugs such as phenytoin, barbiturates, and carbamazepine. [16]"}
{"id": "article-30267_8", "title": "Topiramate -- Administration", "content": "Topiramate is available for the adult and pediatric populations in two oral preparations, immediate-release (taken twice daily) and extended-release (taken once daily). Patients should not crush the tablets since there is a bitter taste. There is a sprinkle capsule formulation that the patient may add to a small amount of soft food; topiramate administration may be without regard to meals. Alcohol should be avoided 6 hours before and after the administration of topiramate. [16] It is important to recognize that some extended-release formulations of topiramate are not bioequivalent.", "contents": "Topiramate -- Administration. Topiramate is available for the adult and pediatric populations in two oral preparations, immediate-release (taken twice daily) and extended-release (taken once daily). Patients should not crush the tablets since there is a bitter taste. There is a sprinkle capsule formulation that the patient may add to a small amount of soft food; topiramate administration may be without regard to meals. Alcohol should be avoided 6 hours before and after the administration of topiramate. [16] It is important to recognize that some extended-release formulations of topiramate are not bioequivalent."}
{"id": "article-30267_9", "title": "Topiramate -- Administration", "content": "Monotherapy for partial onset seizures, primary generalized tonic-clonic seizures: The suggested dose for topiramate in adults and pediatric patients ten years and older is 400 mg/day in two divided doses. A slow titration schedule of 25 to 50 mg/day weekly increments is preferred to decrease the frequency of adverse effects. [17]", "contents": "Topiramate -- Administration. Monotherapy for partial onset seizures, primary generalized tonic-clonic seizures: The suggested dose for topiramate in adults and pediatric patients ten years and older is 400 mg/day in two divided doses. A slow titration schedule of 25 to 50 mg/day weekly increments is preferred to decrease the frequency of adverse effects. [17]"}
{"id": "article-30267_10", "title": "Topiramate -- Administration", "content": "Adjunctive therapy for primary generalized tonic-clonic seizures, partial onset seizures, or Lennox-Gastaut Syndrome: The suggested total daily dose of topiramate as an adjunctive treatment in adults with partial onset seizures is 200 to 400 mg/day & 400 mg/day in two divided doses with primary generalized tonic-clonic seizures. It is suggested that treatment be initiated at a lower dose(25 to 50 mg/day) followed by an up-titration of 25 to 50 mg/day every week. [18] [19]", "contents": "Topiramate -- Administration. Adjunctive therapy for primary generalized tonic-clonic seizures, partial onset seizures, or Lennox-Gastaut Syndrome: The suggested total daily dose of topiramate as an adjunctive treatment in adults with partial onset seizures is 200 to 400 mg/day & 400 mg/day in two divided doses with primary generalized tonic-clonic seizures. It is suggested that treatment be initiated at a lower dose(25 to 50 mg/day) followed by an up-titration of 25 to 50 mg/day every week. [18] [19]"}
{"id": "article-30267_11", "title": "Topiramate -- Administration", "content": "Migraine Prevention: According to American Academy of Neurology guidelines, topiramate is\u00a0an effective therapy for migraine prevention (level A),\u00a0significantly decreasing\u00a0migraine attack frequency and severity. The recommended dose range is 25-50 mg.\u00a0Patients with a favorable response to topiramate pharmacotherapy within 4 to 8 weeks should continue treatment for at least six months to acquire maximum benefit. Dose escalation up to 200 mg may be required in selected patients. [20] According to a consensus from the American Academy of Neurology and American Headache Society guidelines, children\u00a0and adolescents receiving topiramate have a\u00a0decrease\u00a0in headache days and migraine attacks. [21]", "contents": "Topiramate -- Administration. Migraine Prevention: According to American Academy of Neurology guidelines, topiramate is\u00a0an effective therapy for migraine prevention (level A),\u00a0significantly decreasing\u00a0migraine attack frequency and severity. The recommended dose range is 25-50 mg.\u00a0Patients with a favorable response to topiramate pharmacotherapy within 4 to 8 weeks should continue treatment for at least six months to acquire maximum benefit. Dose escalation up to 200 mg may be required in selected patients. [20] According to a consensus from the American Academy of Neurology and American Headache Society guidelines, children\u00a0and adolescents receiving topiramate have a\u00a0decrease\u00a0in headache days and migraine attacks. [21]"}
{"id": "article-30267_12", "title": "Topiramate -- Administration -- Use in Specific Patient Population", "content": "Patients with Hepatic Impairment: Topiramate plasma concentrations may be increased in patients with hepatic impairment. However, the increase\u00a0in plasma concentration is not significant, and no dose adjustment is generally suggested.", "contents": "Topiramate -- Administration -- Use in Specific Patient Population. Patients with Hepatic Impairment: Topiramate plasma concentrations may be increased in patients with hepatic impairment. However, the increase\u00a0in plasma concentration is not significant, and no dose adjustment is generally suggested."}
{"id": "article-30267_13", "title": "Topiramate -- Administration -- Use in Specific Patient Population", "content": "Patients with Renal Impairment: Half of the usual dose is suggested for moderate to severe renal impairment and ESRD.\u00a0As topiramate is removed by dialysis, a supplemental dose may be required during hemodialysis. [22]", "contents": "Topiramate -- Administration -- Use in Specific Patient Population. Patients with Renal Impairment: Half of the usual dose is suggested for moderate to severe renal impairment and ESRD.\u00a0As topiramate is removed by dialysis, a supplemental dose may be required during hemodialysis. [22]"}
{"id": "article-30267_14", "title": "Topiramate -- Administration -- Use in Specific Patient Population", "content": "Pregnancy Considerations: A topiramate dose of less than 200 mg daily does not affect the pharmacokinetic levels of\u00a0oral contraceptive pills that contain 35 micrograms of ethinyl estradiol. The dose\u00a0of topiramate used for migraine prevention (25\u201350 mg) is not supposed to reduce contraceptive efficacy. (ACOG 2020) [23] According to the clinical data from the NAAED (North American Antiepileptic Drug) pregnancy registry, there may be a increased risk of oral cleft (1.4%) when infants are exposed to topiramate. [24] First-trimester exposure to topiramate monotherapy is associated with increased occurrence of cleft lip with or without cleft palate (FDA former Pregnancy Category D). A recent study indicates an increased risk of autism spectrum disorders and intellectual disability due to prenatal exposure to topiramate. [25] Topiramate should be considered in pregnancy after a comprehensive risk-benefit evaluation. [20]", "contents": "Topiramate -- Administration -- Use in Specific Patient Population. Pregnancy Considerations: A topiramate dose of less than 200 mg daily does not affect the pharmacokinetic levels of\u00a0oral contraceptive pills that contain 35 micrograms of ethinyl estradiol. The dose\u00a0of topiramate used for migraine prevention (25\u201350 mg) is not supposed to reduce contraceptive efficacy. (ACOG 2020) [23] According to the clinical data from the NAAED (North American Antiepileptic Drug) pregnancy registry, there may be a increased risk of oral cleft (1.4%) when infants are exposed to topiramate. [24] First-trimester exposure to topiramate monotherapy is associated with increased occurrence of cleft lip with or without cleft palate (FDA former Pregnancy Category D). A recent study indicates an increased risk of autism spectrum disorders and intellectual disability due to prenatal exposure to topiramate. [25] Topiramate should be considered in pregnancy after a comprehensive risk-benefit evaluation. [20]"}
{"id": "article-30267_15", "title": "Topiramate -- Administration -- Use in Specific Patient Population", "content": "Breastfeeding Considerations: Maternal doses of topiramate up to 200 mg daily produce a low concentration in infant serum. Sedation and diarrhea have been reported in breastfed infants, but most infants tolerate the drug in milk well. Monitor the infant for diarrhea, drowsiness, irritability, weight gain, and developmental milestones. Caution is required in exclusively breastfed infants and simultaneous use of antiepileptics or psychotropic drugs. [26]", "contents": "Topiramate -- Administration -- Use in Specific Patient Population. Breastfeeding Considerations: Maternal doses of topiramate up to 200 mg daily produce a low concentration in infant serum. Sedation and diarrhea have been reported in breastfed infants, but most infants tolerate the drug in milk well. Monitor the infant for diarrhea, drowsiness, irritability, weight gain, and developmental milestones. Caution is required in exclusively breastfed infants and simultaneous use of antiepileptics or psychotropic drugs. [26]"}
{"id": "article-30267_16", "title": "Topiramate -- Adverse Effects", "content": "Adverse effects are dose-dependent and differ between epilepsy and migraine patients in trials as the trials used different doses based on the condition. [16]", "contents": "Topiramate -- Adverse Effects. Adverse effects are dose-dependent and differ between epilepsy and migraine patients in trials as the trials used different doses based on the condition. [16]"}
{"id": "article-30267_17", "title": "Topiramate -- Adverse Effects", "content": "The most common adverse effects in epilepsy trials included the involvement of the central nervous system (paresthesia, fatigue, cognitive problems, dizziness, somnolence, psychomotor slowing, memory/concentration difficulties, nervousness, confusion), endocrine/metabolism (weight loss, anorexia), respiratory (infection), miscellaneous (fever, flushing). [27] [28] The most common adverse effects in trials involving migraine patients were paresthesia and dysgeusia. [29] Serious adverse drug reactions include:", "contents": "Topiramate -- Adverse Effects. The most common adverse effects in epilepsy trials included the involvement of the central nervous system (paresthesia, fatigue, cognitive problems, dizziness, somnolence, psychomotor slowing, memory/concentration difficulties, nervousness, confusion), endocrine/metabolism (weight loss, anorexia), respiratory (infection), miscellaneous (fever, flushing). [27] [28] The most common adverse effects in trials involving migraine patients were paresthesia and dysgeusia. [29] Serious adverse drug reactions include:"}
{"id": "article-30267_18", "title": "Topiramate -- Adverse Effects", "content": "Acute myopia and secondary angle-closure glaucoma [30]", "contents": "Topiramate -- Adverse Effects. Acute myopia and secondary angle-closure glaucoma [30]"}
{"id": "article-30267_19", "title": "Topiramate -- Adverse Effects", "content": "Oligohidrosis and hyperthermia: uncommon and reversible with cessation of the drug. [31]", "contents": "Topiramate -- Adverse Effects. Oligohidrosis and hyperthermia: uncommon and reversible with cessation of the drug. [31]"}
{"id": "article-30267_20", "title": "Topiramate -- Adverse Effects", "content": "Metabolic acidosis: due to inhibition of carbonic anhydrase isoenzymes, topiramate can lead to metabolic acidosis secondary to type II renal tubular acidosis, elevated urine pH, reduced urine citrate, hypercalciuria, calcium phosphate stone formation, bone mineralization defects. [32]", "contents": "Topiramate -- Adverse Effects. Metabolic acidosis: due to inhibition of carbonic anhydrase isoenzymes, topiramate can lead to metabolic acidosis secondary to type II renal tubular acidosis, elevated urine pH, reduced urine citrate, hypercalciuria, calcium phosphate stone formation, bone mineralization defects. [32]"}
{"id": "article-30267_21", "title": "Topiramate -- Adverse Effects", "content": "Suicidal behavior and ideation [33]", "contents": "Topiramate -- Adverse Effects. Suicidal behavior and ideation [33]"}
{"id": "article-30267_22", "title": "Topiramate -- Adverse Effects", "content": "Cognitive/neuropsychiatric adverse reactions: influence of topiramate on the hippocampus-related memory processes influence spatial memory but does not significantly affect the learning process. [34]", "contents": "Topiramate -- Adverse Effects. Cognitive/neuropsychiatric adverse reactions: influence of topiramate on the hippocampus-related memory processes influence spatial memory but does not significantly affect the learning process. [34]"}
{"id": "article-30267_23", "title": "Topiramate -- Adverse Effects", "content": "Fetal toxicity: Exposure during pregnancy is associated with congenital malformations and developmental delay. Increased risk of recurrent malformations in future pregnancies. [35]", "contents": "Topiramate -- Adverse Effects. Fetal toxicity: Exposure during pregnancy is associated with congenital malformations and developmental delay. Increased risk of recurrent malformations in future pregnancies. [35]"}
{"id": "article-30267_24", "title": "Topiramate -- Adverse Effects", "content": "Hyperammonemia and encephalopathy: one case report describes a young patient developing metabolic encephalopathy with hypoxic respiratory failure, most likely due to concurrent use of valproic acid and topiramate. Clinicians should be cautious of possible hyperammonemia encephalopathy in patients taking these medications presenting with impaired consciousness and cognitive decline. [4]", "contents": "Topiramate -- Adverse Effects. Hyperammonemia and encephalopathy: one case report describes a young patient developing metabolic encephalopathy with hypoxic respiratory failure, most likely due to concurrent use of valproic acid and topiramate. Clinicians should be cautious of possible hyperammonemia encephalopathy in patients taking these medications presenting with impaired consciousness and cognitive decline. [4]"}
{"id": "article-30267_25", "title": "Topiramate -- Adverse Effects", "content": "Kidney stones: long term topiramate administration could induce urolithiasis; therefore, blood testing for acid-base balance, urinary pH, and citrates is recommended in patients with kidney stones. [36]", "contents": "Topiramate -- Adverse Effects. Kidney stones: long term topiramate administration could induce urolithiasis; therefore, blood testing for acid-base balance, urinary pH, and citrates is recommended in patients with kidney stones. [36]"}
{"id": "article-30267_26", "title": "Topiramate -- Adverse Effects", "content": "Paresthesia: is the most common cause of discontinuation of the drug. [37]", "contents": "Topiramate -- Adverse Effects. Paresthesia: is the most common cause of discontinuation of the drug. [37]"}
{"id": "article-30267_27", "title": "Topiramate -- Adverse Effects", "content": "Adjustment of dose in renal failure: dose adjustment is necessary for patients with moderate-to-severe renal impairment. [38]", "contents": "Topiramate -- Adverse Effects. Adjustment of dose in renal failure: dose adjustment is necessary for patients with moderate-to-severe renal impairment. [38]"}
{"id": "article-30267_28", "title": "Topiramate -- Adverse Effects", "content": "Hepatotoxicity: A literature review indicates that\u00a0<1% of subjects have\u00a0increased\u00a0serum aminotransferase levels during long-term topiramate treatment. The pathophysiology of hepatotoxicity is\u00a0believed\u00a0to be due to the formation of a toxic intermediate metabolic. Cases with lactic acidosis and hyperammonemia may be caused by mitochondrial dysfunction. [39]", "contents": "Topiramate -- Adverse Effects. Hepatotoxicity: A literature review indicates that\u00a0<1% of subjects have\u00a0increased\u00a0serum aminotransferase levels during long-term topiramate treatment. The pathophysiology of hepatotoxicity is\u00a0believed\u00a0to be due to the formation of a toxic intermediate metabolic. Cases with lactic acidosis and hyperammonemia may be caused by mitochondrial dysfunction. [39]"}
{"id": "article-30267_29", "title": "Topiramate -- Adverse Effects -- Drug-Drug Interactions", "content": "Topiramate increases the oral clearance of\u00a0estrogen\u00a0in an oral contraceptive at high dosages and can lead to contraception failure (>200 mg/day). [40] Clearance of topiramate may be reduced when used with amitriptyline. Use with caution. [40] Concurrent administration of topiramate with carbamazepine requires dose adjustments due to reduced topiramate concentrations. [41] Concurrent use of topiramate and metformin increases the risk of metabolic acidosis. [42] Concurrent use of carbonic anhydrase inhibitors like acetazolamide and dorzolamide brinzolamide with topiramate may increase the risk of\u00a0metabolic acidosis and nephrolithiasis. Avoid combination. [11] Concurrent use of topiramate with benzodiazepines, alcohol, thalidomide, and bromperidol can cause sedation and excessive CNS depression.", "contents": "Topiramate -- Adverse Effects -- Drug-Drug Interactions. Topiramate increases the oral clearance of\u00a0estrogen\u00a0in an oral contraceptive at high dosages and can lead to contraception failure (>200 mg/day). [40] Clearance of topiramate may be reduced when used with amitriptyline. Use with caution. [40] Concurrent administration of topiramate with carbamazepine requires dose adjustments due to reduced topiramate concentrations. [41] Concurrent use of topiramate and metformin increases the risk of metabolic acidosis. [42] Concurrent use of carbonic anhydrase inhibitors like acetazolamide and dorzolamide brinzolamide with topiramate may increase the risk of\u00a0metabolic acidosis and nephrolithiasis. Avoid combination. [11] Concurrent use of topiramate with benzodiazepines, alcohol, thalidomide, and bromperidol can cause sedation and excessive CNS depression."}
{"id": "article-30267_30", "title": "Topiramate -- Contraindications", "content": "Topiramate is a relatively safe drug, as the list of absolute contraindications\u00a0is\u00a0minimal. As a carbonic anhydrase inhibitor, topiramate can precipitate metabolic acidosis development and is, therefore, contraindicated in individuals currently with (or prone to experiencing) metabolic acidosis. Other contraindications include those with a history of a proven allergy to topiramate or within six hours before and six hours after alcohol use. [20]", "contents": "Topiramate -- Contraindications. Topiramate is a relatively safe drug, as the list of absolute contraindications\u00a0is\u00a0minimal. As a carbonic anhydrase inhibitor, topiramate can precipitate metabolic acidosis development and is, therefore, contraindicated in individuals currently with (or prone to experiencing) metabolic acidosis. Other contraindications include those with a history of a proven allergy to topiramate or within six hours before and six hours after alcohol use. [20]"}
{"id": "article-30267_31", "title": "Topiramate -- Monitoring", "content": "Baseline and periodic serum bicarbonate levels are required monitoring protocols for individuals on topiramate due to concern for metabolic acidosis. Renal function tests should be monitored.\u00a0According to the American Epilepsy Society, antiepileptic drug-level testing(including topiramate) should not be routinely\u00a0obtained when the seizures are controlled with no adverse effects. However,\u00a0monitoring\u00a0topiramate levels is advised in special cases requiring weight-based\u00a0dose adjustments in young children, patient adherence, polypharmacy, and suspected toxicity.\u00a0Since there is variability in topiramate plasma concentration with concomitant AED use, monitoring plasma concentration may be beneficial for optimizing drug dosage. [14] [43] As patient management is different, obtain serum prolactin levels to differentiate between psychogenic nonepileptic seizures (PNES)\u00a0and\u00a0generalized tonic-clonic or complex partial seizures. [44]", "contents": "Topiramate -- Monitoring. Baseline and periodic serum bicarbonate levels are required monitoring protocols for individuals on topiramate due to concern for metabolic acidosis. Renal function tests should be monitored.\u00a0According to the American Epilepsy Society, antiepileptic drug-level testing(including topiramate) should not be routinely\u00a0obtained when the seizures are controlled with no adverse effects. However,\u00a0monitoring\u00a0topiramate levels is advised in special cases requiring weight-based\u00a0dose adjustments in young children, patient adherence, polypharmacy, and suspected toxicity.\u00a0Since there is variability in topiramate plasma concentration with concomitant AED use, monitoring plasma concentration may be beneficial for optimizing drug dosage. [14] [43] As patient management is different, obtain serum prolactin levels to differentiate between psychogenic nonepileptic seizures (PNES)\u00a0and\u00a0generalized tonic-clonic or complex partial seizures. [44]"}
{"id": "article-30267_32", "title": "Topiramate -- Monitoring", "content": "Monitor for a reduction in the frequency of the most\u00a0debilitating seizures (drop attacks and tonic-clonic seizures) when topiramate is used for\u00a0Lennox-Gastaut syndrome (LGS) [19] Monitor for a reduction in\u00a0the frequency and severity of headaches.\u00a0A decrease\u00a0in the frequency of migraine days is a key measure of the efficacy of migraine prevention. [45]", "contents": "Topiramate -- Monitoring. Monitor for a reduction in the frequency of the most\u00a0debilitating seizures (drop attacks and tonic-clonic seizures) when topiramate is used for\u00a0Lennox-Gastaut syndrome (LGS) [19] Monitor for a reduction in\u00a0the frequency and severity of headaches.\u00a0A decrease\u00a0in the frequency of migraine days is a key measure of the efficacy of migraine prevention. [45]"}
{"id": "article-30267_33", "title": "Topiramate -- Toxicity", "content": "Fortunately, there are no reports of fatalities with topiramate monotherapy. Symptoms of toxicity include sedation, speech disturbance, blurred vision, agitation, ataxia, convulsions, and abdominal pain. ABG analysis in topiramate overdose usually demonstrates\u00a0hyperchloraemic normal anion gap metabolic acidosis. [46]", "contents": "Topiramate -- Toxicity. Fortunately, there are no reports of fatalities with topiramate monotherapy. Symptoms of toxicity include sedation, speech disturbance, blurred vision, agitation, ataxia, convulsions, and abdominal pain. ABG analysis in topiramate overdose usually demonstrates\u00a0hyperchloraemic normal anion gap metabolic acidosis. [46]"}
{"id": "article-30267_34", "title": "Topiramate -- Toxicity", "content": "In seven cases of topiramate toxicity observed by Polish Poison Control Centers, the most common symptom for topiramate toxicity was somnolence (66.7%), along with agitation, mydriasis, and vertigo (33.4%). One individual experienced three tonic-clonic seizures. There were no fatalities or long-term consequences observed.\u00a0A specific antidote is not currently available. [47] If symptoms are refractory to ongoing treatment, hemodialysis can reduce topiramate concentrations. [22]", "contents": "Topiramate -- Toxicity. In seven cases of topiramate toxicity observed by Polish Poison Control Centers, the most common symptom for topiramate toxicity was somnolence (66.7%), along with agitation, mydriasis, and vertigo (33.4%). One individual experienced three tonic-clonic seizures. There were no fatalities or long-term consequences observed.\u00a0A specific antidote is not currently available. [47] If symptoms are refractory to ongoing treatment, hemodialysis can reduce topiramate concentrations. [22]"}
{"id": "article-30267_35", "title": "Topiramate -- Enhancing Healthcare Team Outcomes", "content": "Topiramate is FDA-approved for various types of epilepsy, migraine, and Lennox-Gastaut syndrome; however, it has numerous off-label uses and a significant adverse drug reaction profile. Therefore, healthcare professionals must continually educate themselves on the most up-to-date information regarding new medical information. Clinicians should prescribe topiramate for the specific indication. Neurologist and epileptologist consultation is required in refractory seizures and seizures associated with Lennox-Gastaut syndrome. For various off-label uses, consultation with\u00a0other specialties may be essential. Nursing can monitor for any adverse events and patient compliance. Pharmacists play a crucial role in verifying the medication reconciliation and reporting to the prescriber if there is any significant interaction.", "contents": "Topiramate -- Enhancing Healthcare Team Outcomes. Topiramate is FDA-approved for various types of epilepsy, migraine, and Lennox-Gastaut syndrome; however, it has numerous off-label uses and a significant adverse drug reaction profile. Therefore, healthcare professionals must continually educate themselves on the most up-to-date information regarding new medical information. Clinicians should prescribe topiramate for the specific indication. Neurologist and epileptologist consultation is required in refractory seizures and seizures associated with Lennox-Gastaut syndrome. For various off-label uses, consultation with\u00a0other specialties may be essential. Nursing can monitor for any adverse events and patient compliance. Pharmacists play a crucial role in verifying the medication reconciliation and reporting to the prescriber if there is any significant interaction."}
{"id": "article-30267_36", "title": "Topiramate -- Enhancing Healthcare Team Outcomes", "content": "The brand name of topiramate may be confused with the brand name of a commonly used extended-release beta blocker. (ISMP look-alike-sound-alike names). Consequently, pharmacists must be careful while dispensing the drug. [48] Emergency medicine physicians and nurses should rapidly stabilize the patient in an overdose. Critical care physicians and medical toxicologists are crucial in managing patients with massive overdoses. Once the patient is stable, psychiatric evaluation and support are necessary. Interprofessional coordination between clinicians (MDs, DOs, NPs, PAs), nurses, pharmacists, specialists, and other healthcare workers is necessary to decrease adverse events and improve patient outcomes related to topiramate treatment. [Level 5]", "contents": "Topiramate -- Enhancing Healthcare Team Outcomes. The brand name of topiramate may be confused with the brand name of a commonly used extended-release beta blocker. (ISMP look-alike-sound-alike names). Consequently, pharmacists must be careful while dispensing the drug. [48] Emergency medicine physicians and nurses should rapidly stabilize the patient in an overdose. Critical care physicians and medical toxicologists are crucial in managing patients with massive overdoses. Once the patient is stable, psychiatric evaluation and support are necessary. Interprofessional coordination between clinicians (MDs, DOs, NPs, PAs), nurses, pharmacists, specialists, and other healthcare workers is necessary to decrease adverse events and improve patient outcomes related to topiramate treatment. [Level 5]"}
{"id": "article-30267_37", "title": "Topiramate -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Topiramate -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}